![Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial - The Lancet Neurology Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial - The Lancet Neurology](https://www.thelancet.com/cms/attachment/2000992340/2003665351/gr1.gif)
Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial - The Lancet Neurology
SÚHRN CHARAKTERISTICKÝCH VLASTNOSTÍ LIEKU 1. NÁZOV LIEKU Pramipexol Teva Pharma 0,26 mg Pramipexol Teva Pharma 0,52 mg Pram
![P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease | Advances in Therapy P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease | Advances in Therapy](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs12325-022-02097-2/MediaObjects/12325_2022_2097_Fig3_HTML.png)
P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease | Advances in Therapy
Písomná informácia pre používateľa Pramipexol Teva Pharma 0,26 mg Pramipexol Teva Pharma 0,52 mg Pramipexol Teva Pharma 1,
![Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial - The Lancet Neurology Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial - The Lancet Neurology](https://www.thelancet.com/cms/attachment/2064159792/2065870029/gr1.gif)